The WACC of Fusen Pharmaceutical Co Ltd (1652.HK) is 8.1%.
| Range | Selected | |
| Cost of equity | 11.10% - 14.80% | 12.95% |
| Tax rate | 16.80% - 21.30% | 19.05% |
| Cost of debt | 5.00% - 7.00% | 6.00% |
| WACC | 6.9% - 9.2% | 8.1% |
| Category | Low | High |
| Long-term bond rate | 2.9% | 3.4% |
| Equity market risk premium | 6.0% | 7.0% |
| Adjusted beta | 1.38 | 1.57 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 11.10% | 14.80% |
| Tax rate | 16.80% | 21.30% |
| Debt/Equity ratio | 1.5 | 1.5 |
| Cost of debt | 5.00% | 7.00% |
| After-tax WACC | 6.9% | 9.2% |
| Selected WACC | 8.1% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 1652.HK:
cost_of_equity (12.95%) = risk_free_rate (3.15%) + equity_risk_premium (6.50%) * adjusted_beta (1.38) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.